• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Medpace Buys Medical Device CRO Symbios

Medpace Buys Medical Device CRO Symbios

April 7, 2010
CenterWatch Staff

Cincinnati-based contract research organization (CRO) Medpace acquired medical device CRO Symbios for an undisclosed amount. Symbios was advised by Fairmount Partners in this transaction.

Symbios supports medical device research with experience in pre-market, post-approval and post-market clinical trials. The company will continue to operate out of its Minneapolis, Minn., headquarters. Symbios’ founder and CEO Ryan Wilson and his management team will continue to lead Medpace’s medical device business, now named Symbios Clinical, as a member of the Medpace group of companies.

“The ability of Medpace to tap into this innovative company for benefit of our existing and new Sponsors will be valuable as yet another service area for Medpace, and allow Symbios to benefit from our established global infrastructure,” said Medpace president and CEO August Troendle in a statement.

Medpace offers services in phase I to IV clinical trial management, bio-imaging, central laboratory and clinical pharmacology. The CRO has European headquarters in The Netherlands, Asian headquarters in Singapore and regional offices throughout Europe, Asia, Australia, South Africa and the Americas.

Earlier this year, the company acquired Germany-based CRO Medical Consulting Dr. Schlichtiger. At the time, Medpace had 1,000 employees worldwide but announced plans to almost double its headcount by 2014.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing